Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28054665 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL27989779 | 0.89 | HSD17B10 (0.40) | ATMHSD17B10HPGDSMN1; SMN2EPHX1 | |
| SCHEMBL25936315 | 0.86 | PDE8B (0.47) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL12528533 | 0.86 | PDE8B (0.47) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL282977 | 0.86 | POLB (0.51) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL192841 | 0.86 | POLB (0.51) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL282976 | 0.86 | POLB (0.51) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL6597261 | 0.86 | PDE8B (0.47) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL378749 | 0.86 | PDE8B (0.47) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL21597007 | 0.84 | PDE8B (0.47) | PDE8BKDM1AATMHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531562-B2 | Such as 2-(1-tert- butoxycarbonylpiperidin-2-yl)ethyl 5-norbornene-2-carboxylate; photolithography; etching/heat resistance; semiconductors | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2003-03-11 | — | — | US | claimed |
| US-20020151666-A1 | Novel photoresist monomer, polymer thereof and photoresist composition containing it | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2002-10-17 | — | — | US | claimed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-6531562-B2 | Such as 2-(1-tert- butoxycarbonylpiperidin-2-yl)ethyl 5-norbornene-2-carboxylate; photolithography; etching/heat resistance; semiconductors | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2003-03-11 | — | — | US | disclosed |
| US-20020151666-A1 | Novel photoresist monomer, polymer thereof and photoresist composition containing it | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2002-10-17 | — | — | US | disclosed |
| US-6448352-B1 | BICYCLIC POLYMERS FROM SUCH AS 2-(1-TERT-BUTOXYCARBONYL-PIPERIDIN-2-YL)ETHYL 5-NORBORNENE-2-CARBOXYLATEALKOXYALKYL, NON-PIPERIDINYL BICYCLOCARBOXY MONOMERS AND MALEIC ANHYDRIDE; ETCHING AND HEAT RESISTANCE; ENHANCED POST EXPOSURE DELAY | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PDE8B 4151/4885KDM1A 2861/4885ATM 4617/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PDE8B 4151/4885KDM1A 2861/4885ATM 4617/4885 |
| US-20020151666-A1 | Novel photoresist monomer, polymer thereof and photoresist composition containing it | HEATR1, CD79B, PYCR1 | PDE8B 4379/4885KDM1A 1127/4885ATM 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.